GENORA

  • Research type

    Research Study

  • Full title

    Genomic Instability in Obesity:Reversibility Assessment in Adolescents

  • IRAS ID

    351672

  • Contact name

    Emauela Volpi

  • Contact email

    E.Volpi@westminster.ac.uk

  • Sponsor organisation

    University of Westminster

  • Duration of Study in the UK

    3 years, 0 months, 30 days

  • Research summary

    Adolescent obesity is a growing global health concern. In the UK, over one in three teenagers are entering adulthood with excessive weight, with obesity rates peaking at 21.4% by age 17 and an additional 14.3% categorized as overweight. This significantly increases the risk of obesity persisting into adulthood, which is associated with health complications such as type 2 diabetes, cardiovascular diseases, and a heightened risk of certain cancers later in life. Emerging research indicates that adolescent obesity may be an independent risk factor for cancer due to its harmful effects on DNA.

    Excess body fat can trigger chronic low-grade inflammation, disrupting cytokines and chemokines balance that regulate the body’s immune responses. This imbalance leads to the increased production of reactive oxygen and nitrogen species (ROS/RNS), which can damage DNA. Persistent DNA damage contributes to genomic instability, a key factor in cancer development. While weight loss in adults has shown potential in reversing DNA damage, its effectiveness in childhood and adolescence has not bee explored yet.

    This study will examine whether weight loss can reverse DNA damage in adolescents with clinical obesity. It will compare three different weight-loss interventions: lifestyle changes, pharmacological treatments, and metabolic surgery. Adolescents aged 13–18 undergoing these interventions at King’s College and Bart’s hospitals will be recruited (Participation is Voluntary). Biological samples, including saliva, urine, and opportunistic blood samples, will be collected at baseline, 6 months, and end of the study for the lifestyle and pharmacological groups. For the surgery group, samples will be collected at baseline, 6, 12, and 18 (or 24) months during routine follow-ups.

    This study will examine how weight loss interventions affect DNA stability, inflammation, and nutrients, aiming to improve personalized treatment strategies for obesity-related diseases, including cancer, in young people.

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    25/PR/1556

  • Date of REC Opinion

    10 Feb 2026

  • REC opinion

    Further Information Favourable Opinion